CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. [electronic resource]
Producer: 20060306Description: 1473-9 p. digitalISSN:- 0269-9370
- Adjuvants, Immunologic -- therapeutic use
- Adolescent
- Adult
- Antiretroviral Therapy, Highly Active -- adverse effects
- CD4 Lymphocyte Count
- Double-Blind Method
- Female
- HIV Infections -- complications
- Hepatitis B -- complications
- Hepatitis B Surface Antigens -- blood
- Hepatitis B Vaccines -- administration & dosage
- Humans
- Lymphocyte Activation
- Male
- Middle Aged
- Oligodeoxyribonucleotides -- therapeutic use
- RNA, Viral -- blood
- Vaccines, Synthetic -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.